The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Gastrointestinal Therapeutics Market Change Between 2026 And 2030?
The gastrointestinal therapeutics market has experienced significant growth in recent years. This market is set to expand from $42.3 billion in 2025 to $44.72 billion in 2026, progressing at a compound annual growth rate (CAGR) of 5.7%. The historical expansion can be attributed to several factors including the restricted availability of biologics and advanced gastrointestinal therapies, a rising incidence of acid reflux and ulcers, a reliance on hospital and clinic-based treatment, increasing awareness concerning digestive health, and the widespread use of traditional over-the-counter antacids and laxatives.
The gastrointestinal therapeutics market is set for considerable expansion in the coming years. It is projected to reach $55.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This anticipated growth is driven by several factors, including the development of targeted biologics and immunotherapies, the increasing number of ambulatory surgical centers and diagnostic laboratories, the growing adoption of oral and intravenous delivery systems, expanding online pharmacy presence, and innovations in probiotic and digestive enzyme formulations. Key trends for the forecast period include a rising incidence of gastrointestinal disorders, increased utilization of biologics and advanced therapies, the expansion of over-the-counter therapeutic options, a heightened focus on personalized gastrointestinal treatments, and the growth of online and retail pharmacy distribution channels.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp
What Market Drivers Are Helping Shape The Gastrointestinal Therapeutics Market Expansion?
The increasing incidence of inflammatory bowel conditions is anticipated to fuel the expansion of the gastrointestinal therapeutics market moving forward. Inflammatory bowel disease (IBD) is a persistent ailment that causes inflammation in the digestive tract, primarily encompassing Crohn’s disease and ulcerative colitis. The surge in inflammatory bowel diseases is attributed to genetic susceptibility, resulting in an abnormal immune response to gut microbes. Gastrointestinal therapeutics assist in managing and treating bowel conditions by targeting underlying inflammation, regulating digestive functions, and easing associated symptoms to enhance patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Therefore, the rise in inflammatory bowel diseases is propelling the growth of the gastrointestinal therapeutics market.
How Is The Gastrointestinal Therapeutics Market Distributed Across Key Segments?
The gastrointestinal therapeutics market covered in this report is segmented –
1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics
2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products
2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics
Which Trends Are Supporting The Evolution Of The Gastrointestinal Therapeutics Market?
Major companies operating within the gastrointestinal therapeutics market are prioritizing the development of innovative therapies, such as sustained-release (SR) fixed-dose combination capsules, with the goal of improving patient adherence and increasing treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications designed to gradually release multiple active ingredients over time, thereby maintaining consistent drug levels and reducing the frequency of dosing. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based company specializing in pharmaceutical preparation manufacturing, launched rabeprazole + levosulpiride SR capsules for the treatment of gastrointestinal disorders in India. This specific formulation combines rabeprazole, which acts as a proton pump inhibitor to decrease stomach acid, with levosulpiride, a prokinetic agent that enhances gut motility. Together, these components deliver effective relief from symptoms including heartburn, acid reflux, bloating, and indigestion. This combination therapy is widely prescribed for the management of gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.
Which Companies Form The Competitive Landscape Of The Gastrointestinal Therapeutics Market?
Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation
Access The Complete Gastrointestinal Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report
Which Region Stands As The Largest Contributor To The Gastrointestinal Therapeutics Market?
North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Gastrointestinal Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp
Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company
Gastrointestinal Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market
Gastroparesis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report
Digestive And Intestinal Remedies Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model